Management of Coronary Artery Disease with Hypertension and Tachycardia

Primary Concern: Tachycardia Management

Beta-blockers are the drug of first choice in patients with CAD and angina, particularly for at least 6 months post-MI, because they provide secondary prevention benefits that calcium channel blockers cannot match 2
The American Heart Association explicitly states that beta-blockers are more appropriate than calcium channel blockers for secondary cardiac protection in CAD patients 2

Amlodipine is safe as add-on therapy when beta-blockers alone do not achieve blood pressure control, according to the American College of Cardiology 1, 3
Amlodipine can be used when beta-blockers are contraindicated, not tolerated, or cause unacceptable side effects, as stated by the European Society of Cardiology 4
Amlodipine can be added after beta-blocker therapy is optimized and additional antihypertensive effect is needed, as recommended by the American Heart Association 2

The PRAISE trial showed amlodipine was safe in patients with severe systolic heart failure, neither improving nor worsening survival, according to the American College of Cardiology 1, 3
The ALLHAT trial demonstrated equivalent cardiovascular outcomes with amlodipine compared to other antihypertensive agents in hypertensive patients, as reported by the National Institutes of Health 2

Nondihydropyridine calcium channel blockers (diltiazem, verapamil) should be avoided in patients with ischemic systolic heart failure due to negative inotropic properties and increased risk of worsening heart failure, as warned by the American Heart Association 1, 3
Dihydropyridine calcium channel blockers (amlodipine, felodipine) are safe because they lack significant negative inotropic effects, according to the European Society of Cardiology 1

Start with a beta-blocker (first-line for CAD + tachycardia), as recommended by the American College of Cardiology 2
Add amlodipine if blood pressure remains >140/90 mmHg on beta-blocker alone, according to the American Heart Association 1, 3
Consider ACE inhibitor or ARB as third agent if needed for additional blood pressure control, as suggested by the European Society of Cardiology 1, 3
Target blood pressure <140/90 mmHg, with consideration for <130/80 mmHg in appropriate patients, as recommended by the American College of Cardiology 1

Triple therapy with ACE inhibitor/ARB, calcium channel blocker, and thiazide diuretic can be effective and well-tolerated when needed, according to the American Heart Association 3